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Aihara, Kazunod Shimada, Hitoshi Satoh, Hiroyuki Daida, Juntendo Universi~ Tokyo, 
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Constrictive remodeling plays a prominent role in restenosis after balloon angioplasty. 
The sevedty of constrictive remodeling correlates with endothelium dependent relaxation 
and collagen density. At the site of coronary angioplasty, inflammatory cytokine can 
induce chain reaction that may cause restenosis, and PPAR-a activation suppresses the 
inflammatory cytokines. Fenofibrate is a hypolipidemic drug, the PPAR+a specific ligand 
that has been shown to enhance PPAR-a activity. Thus, fenofibrate may be proposed as 
a promising strategy against restenosis. We tested fenofibrate for its efficacy on remodel- 
ing, expression of collagen synthesis, and endothelial function in 14 coronary arteries of 
7 pigs (1000rag/day orally beginning 7d pre-angioplasty) and was compared to placebo 
(14 coronaries, 7 pigs) 28 days after angioplasty. Quantitative intravascular ultrasound 
revealed fenofibreta increased lumen area compared with placebo (4.84±0.26 vs. 
4.25±0.33mm2). Remodeling index was defined as the ratio the external elastic mem- 
brane (EEM) area at the lesion to that at the proximal reference site. EEM area 
(7.91±0.64 vs. 6.12±0.56mm2) and remodeling index (1.10 vs. 0.89) were significantly 
greater in fenofibreta than that in placebo. Histopathologic assessment showed that 
PPAR-a in neointima was up-regulated in fenofibrata group whereas there was a few 
positive cells in placebo. Collagen content was measured by a digital subtraction method 
(sirius red-stained sections) and was significantly decreased in the treated vessels com- 
pared to controls (75±11 vs. 99±9%). Assessment of endothelial function in vivo was per- 
formed 4 weeks after angioplasty. Balloon injured coronary arteries in placebo group 
showed an impaired relaxation to acetylcholine while relaxation to acetylchciine was 
reversed in the injured vessels derived from fenofibrate treated pigs (4.2±8.3 vs. 
31.5±13%). In conclusion, pharmacological activation of PPAR-a inhibited constrictive 
remodeling after balloon angioplasty through reduction collagen synthesis and recovery 
of endothelium-dependent relaxation. 
1198-25 Effects of Simvaetatln on the Response to Arterial 
Injury in Wild-Type (WT) and Apol ipoprotein E-Deficient 
(ApoE0) Mice 
Robin P. Choudhurv. Angela L. Carrelli, Joshua Stem, Raymond Soccio, Igor 
Chereshnev, Valerie Elmalem, John T. Fellon, Edward A. Fisher, Ernane D. Reis, Mount 
Sinai School of Medicine, New York, New York. 
BACKGROUND. Statins suppress cell proliferation and promote endothelial restoration 
independent of cholesterol-lowering. We hypothesized that these properties may inhibit 
intimal hyperplasia after arterial injury. Normciipidamic (WT) and hyperiipidemic (ApoE0) 
mice were studied. Since ApoE0 mice lack the major ligand for LDL receptors, we 
hypothesized that 'simvastatin would not alter lipoprotein levels. 
METHODS. Wild type (n=40) and ApoE0 (n=40) mice were fed chow. At age 10 weeks, 
20 from each group were converted to chow containing simavastatin (100mg/kg/day). At 
age 12 weeks all mice underwent bilateral transluminal femoral artery injury with a 0.010" 
angioplasty guidewire. Arteries were perfusion-fixod after 4 weeks and analyzed. 
RESULTS. (1)WT mice: Plasma cholesterol (mean/SD mg/dL) was similar in treated 
(101/19.8) and untreated (77.4/16.2) mice. FPLC showed no differences in lipoprotein 
profiles. Statins inhibit HMGCoA reductase and induce its transcription+ To demonstrate 
an effective simvasfatin dose, mRNA for HMGCoA Reductase was quantified by reverse 
transcriptaea-PCR and shown to be increased 5.4-fold (P<0.0001) by simvastatin. Intimal 
hyperplasia, (IH = ratio of intima to media area) was similar in simvastatin treated (0.8+/- 
0.4) and untreated (0.7+/-0.4) mice. 
(2)ApoE0 mice: Plasma cholesterol in untreated mice (658/258) was higher than in WTs 
(P<0.0001). Unexpectedly, simvastatin treatment caused a further increase to 1094/ 
225.7 (P<0.0001). Untreated APOE0 mice had higher I/M ratios than WTs (1.31 +/-0.66 vs 
0.7+/-0.4, P<0.001 ). This effect was exaggerated in the paradoxically hyperlipidemic sim- 
vastatin-treated mice whose intimal area was increased by a further 50% (P<0.02). 
CONCLUSION. In WT mice, simvastatin: (1) induced HMGCoA reductase, (2) had no 
effect on plasma cholesterol or lipoprotein profiles (3) did not reduce intimal hyperplasia+ 
In ApoE0 mice, (I) hyperlipidemia promoted IH (2) simvastatin worsened hyperlipidemia 
and IH. (3) It is speculated that in ApoE0 mice, where lipoprotein clearance is abnormal, 
small increases in lipoprotein production, secondary to upregulation of synthetic 
enzymes cause an increase in plasma cholesterol. 
1198-26 Photodynamic Therapy of Pig Coronary Arteries 
Induces Apoptosis  of Endothelial and Vascular Smooth 
Muscle Cells 
Richard J. Mansfield. Nadim Msfik, Alexander Mosse, Andrzej Loesch, Stephen Bown, 
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Cardiovascular Research, Northern General Hospital, Sheffield, United Kingdom. 
Photodynamic therapy (PDT) may be useful in preventing restenosis. It involves the local 
activation of a systemically administered photosensitiser by non-thermal aser light. It 
induces endothelial denudation and vascular smooth muscle cell (SMC) ablation without 
inflammation with tissue architecture returning to normal within 4 weeks. We have shown 
previously that endovascular PDT inhibits neointima after experimental balloon injury. 
The mechanism of cell loss following PDT is the subject of this study. 
Methods: 6 Large White-Landrece pigs (20-30Kg) were sensitised with iv 5-aminolae- 
vulinic acid (60mg/Kg). Coronary angiography was performed 4 - 6 hours later and arter- 
ies randomised to either 50J/cm2 red light from a laser via a centering balloon catheter, 
sham illumination or no further treatment. Artedes from each group were harvested at 1,3 
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or 20 hours and processed for TUNEL staining including co-locelisation immunohis- 
tochemistry for endothelial cells (von Willebrand factor - vWF), SMC (¢x-actin) and inflam- 
matory macrophages (MAC 387), DNA fragmentation and transmission electron 
microscopy ('rEM) to look for apoptosis. Mean cell counts were dedved from 4 high 
power fields (HPF-x40 magnification), per section. 
Results: There was no apoptosis in untreated vessels. 1 hour after PDT there was clear 
TUNEL staining of condensed nuclei of vWF-positive endothelial cells. Medial TUNEL 
and ~-actin positive cells were seen at 3 and 20 hours with apoptotic cells constituting 
5+4% and 10.3% of the total cells respectively. There were significantly fewer medial 
cells, with loss of c<-actin positive staining, at 20 hours (45±14 vst 10-J:12 and 102:1:15 for 
PDT treated, sham illuminated and control arteries respectively, p<0.001 ). DNA fragmen- 
tation was seen at 20 hours only. Adventitial TUNEL positive cells were seen at 20 hours 
(9.7%). inflammatory macrophages were not seen. Morphological features of endothelial 
and SMC apoptosis were confirmed on TEM at each time point after PDT. 
Conclusion: PDT induces programmed cell death in endothelial and vascular smooth 
muscle cells. Reducing arterial cellularity by apoptosis may be one mechanism by which 
PDT has beneficial effects in restenosis. 
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A Phase II Double Blind Placebo-Control led Multicenter 
Study of the Anti-PDGF-~R DI-Fab'-PEG Conjugate 
CDP860 (25 mg/kg) Dosed Intravenously in Patients 
Undergoing Elective Coronary Stent Placement 
Patrick W. Serruvs. Ill. Guy Heyndrickx, Hans Bonnier, Matty Vrolix, Frank Van den 
Brenden, Victor Legrend, Claude Hanet, Hans Te Riele, Michael Vandormael, Ivan De 
Scheerder, Celitech Research and Development, Slough, Berkshire, United Kingdom. 
Coronary restenosis following angioptasty or stenting is a common problem which fre- 
quently requires re-intervention. A major element of restenosis is neointimal hyperplasia 
which particularly follows stant placement. In baboon models of rasfenosis, administra- 
tion of an anti-PDGF-13 -receptor-blocking antibody potently inhibited vascular smooth 
muscle migration and subsequent neointimal hyperplasia.CDP860 consists of a human- 
ised antibody di-Fab' against the I~ +subunit of platelet derived growth factor receptor 
attached to polyethylene glycol. It is being evaluated in a phase II, double-blind placebo 
controlled trial in 10 centres in Belgium and the Netherlands for the prevention of within- 
stent restenosis. The pdmary efficacy endpoint is intravascular ultrasound comparison of 
mean percentage in-stent volume obstruction (PIVO) due to neoinUmal hyperplasia 6 
months after dosing in CDP860 and placebo treated groups. Secondary endpoints are 
other IVUS and QCA parameters, incidence of restenosis, MACE and anginal status. 
Based on expected PIVO of 28.3%, it is calculated that 100 evaluable patients will be 
necessary to detect a 33% reduction by CDP860, with 85% power, at two sided c~ of 0.05. 
Patients with stable or unstable angina pectoris (Breunwald Class 1-3:B-C) or docu- 
mented silent ischaemia who are eligible for elective sfent placement in one or more cor- 
onary lesions, not treated within the last year in one or more native vessels, receive a 
single intravenous infusion of 25mg/kg COP860 or placebo just prior to the procedure. 
Recruitment has been completed with 145 patients dosed. Treatment with study medica- 
tion appears not to be associated with any serious safety concern. The study remains 
blinded. Six-month follow-up results will be presented at the meeting. 
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872-2 Combinat ion of VEGF-C Gene Transfer and Treatment 
With the PDGF Receptor Kinase Inhibitor STI571 Leads 
to Persistent Reduction in Neointima Formation in 
Balloon-Denunded Rabbit Aorta 
Olli P. Leooanen. Mikko O. Hiltunen, Tuomas T. Rissanen, Juha Rutanen, Mikko P. 
Turunen, Tobias Sj(~blom, Josef Broeggen, Marianne Cadsson, Elisabeth Buchdunger, 
David Bergqvisf, Kad Alitalo, Cad-Henrik Heldin, Ame (Sstman, Seppo YIS-Herttuala, 
Ludwig institute for Cancer Research, Uppsala, Sweden, A.I. Virtanen Institute for 
Molecular Sciences, Kuopio, Finland. 
Background: Several new therapies against naointima formation, such as inhibition of 
PDGF signaling to prevent smooth muscle cell growth, or application of endothelial cell 
mitogens of the VEGF family, have been recently developed and tested in various animal 
models. However, with these therapies lesion recurrence or 'catch-up growth' has been 
observed. 
Methode: To evaluate the effects of combining inhibition of PDGF signaling with local 
application of VEGF.C on intimal thickening a rabbit model of restenosis was used. 42 
rabbits were put on hypercholesteroiemic diet and subjected to balloon injury. For VEGF- 
C application, local transfection with VEGF-C encoding replication-deficient adenovi- 
ruses was used. Inhibition of PDGF signalling was obtained by a 3-week course of sys- 
temic treatment with STI571, a potent low molecular weight inhibitor of PDGF-receptor 
tyrosine kinase. 
Results: At an endpoint of 6 weeks after injury none of the therapies alone reduced inti- 
real thickening. However, the combined treatment led to a persistent reduction (54% vs. 
